Small Methods,
Journal Year:
2023,
Volume and Issue:
8(8)
Published: Dec. 1, 2023
Immune
checkpoint
blockade
(ICB)
therapy
for
tumors
has
arisen
in
growing
interest.
However,
the
low
response
rate
of
to
ICB
is
mainly
attributed
inhibitory
infiltration
immune
cells
tumor
microenvironment
(TME).
Despite
promising
benefits
ICB,
therapeutic
effects
antibodies
are
dependent
on
a
high
dose
and
long-term
usage
clinic,
thereby
leading
immune-related
adverse
effects.
Accordingly,
combined
with
nano-delivery
systems
could
be
used
overcome
T
cell
exhaustion,
which
reduces
side
higher
rates
patients.
In
this
review,
authors
aim
exhaustion
TME
via
modulation
enhanced
immunotherapy.
Several
strategies
summarized
combine
further
enhance
immunotherapy:
a)
expressing
surface
systems;
b)
loading
inhibitors
into
c)
gene-editing
technology
d)
mediated
modulation.
Taken
together,
might
strategy
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: July 22, 2024
Abstract
Cytokines
are
critical
in
regulating
immune
responses
and
cellular
behavior,
playing
dual
roles
both
normal
physiology
the
pathology
of
diseases
such
as
cancer.
These
molecules,
including
interleukins,
interferons,
tumor
necrosis
factors,
chemokines,
growth
factors
like
TGF-β,
VEGF,
EGF,
can
promote
or
inhibit
growth,
influence
microenvironment,
impact
efficacy
cancer
treatments.
Recent
advances
targeting
these
pathways
have
shown
promising
therapeutic
potential,
offering
new
strategies
to
modulate
system,
progression,
overcome
resistance
conventional
therapies.
In
this
review,
we
summarized
current
understanding
implications
cytokine
chemokine
signaling
By
exploring
molecules
biology
response,
highlighted
development
novel
agents
aimed
at
modulating
combat
The
review
elaborated
on
nature
cytokines
promoters
suppressors
tumorigenesis,
depending
context,
discussed
challenges
opportunities
presents
for
intervention.
We
also
examined
latest
advancements
targeted
therapies,
monoclonal
antibodies,
bispecific
receptor
inhibitors,
fusion
proteins,
engineered
variants,
their
metastasis,
microenvironment.
Additionally,
evaluated
potential
combining
therapies
with
other
treatment
modalities
improve
patient
outcomes.
Besides,
focused
ongoing
research
clinical
trials
that
pivotal
advancing
our
application
cytokine-
chemokine-targeted
patients.
Theranostics,
Journal Year:
2023,
Volume and Issue:
13(5), P. 1520 - 1544
Published: Jan. 1, 2023
Immunotherapy
has
achieved
great
success
recently
and
opened
a
new
avenue
for
anti-tumor
treatment.
Programmed
cell
death
1/programmed
ligand
1
(PD-1/PD-L1)
are
typical
immune
checkpoints
that
transmit
coinhibitory
signals,
muting
the
host
immunity.
Monoclonal
antibodies
block
PD-1/PD-L1
axis
have
benefited
many
patients
with
different
tumor
diseases.
However,
objective
response
rate
is
still
unsatisfactory.
In
this
review,
we
summarize
three
strategies
targeting
PD-L1
based
on
forms
of
various
regulating
mechanisms
to
enhance
therapeutic
effect,
including
blockade
interaction
between
PD-1,
downregulation
expression
degradation
mature
PD-L1.
Thereinto,
describe
variety
materials
been
designed
target
PD-L1,
antibodies,
nanoparticle,
peptide,
aptamer,
RNA,
small
molecule.
Additionally,
list
drugs
regulation
capacity
used
in
clinical
ongoing
studies
explore
other
alternatives
besides
anti-PD-L1
monoclonal
antibodies.
Moreover,
discuss
associated
opportunities
cancer
combination
therapy
modalities
such
as
chemotherapy,
radiotherapy,
photodynamic
(PDT)
photothermal
(PTT),
these
conventional
or
emerging
capable
increasing
cells
by
altering
microenvironment
(TME),
would
display
synergistic
effect.
At
last,
give
brief
summary
outlook
regarding
research
status
future
prospect
immunotherapy.
Advanced Functional Materials,
Journal Year:
2023,
Volume and Issue:
34(1)
Published: Sept. 15, 2023
Abstract
The
therapeutic
application
of
STING
agonists
in
various
malignancies
has
been
limited
by
factors
such
as
the
inability
systemic
administration
and
immunosuppressive
tumor
microenvironment.
Herein,
this
work
reports
a
mesoporous
polydopamine‐based
multifunctional
nanoplatform
loaded
with
agonist
MSA‐2
chelated
Mn
2+
for
synergistic
photothermal
activation‐based
immunotherapy.
effectively
delivers
to
site
intelligently
releases
its
contents
through
acid
degradation,
facilitated
effect.
Additionally,
thermal
ablation
tissue
can
induce
immunogenic
cell
death,
which
helps
alleviate
microenvironment,
thereby
enhancing
efficacy
MSA‐2.
Furthermore,
works
dual‐acting
sensitizer
MRI
contrast
agent
not
only
boosts
immune
response
but
also
allows
real‐time
tracking
nanoplatform.
This
strategy
is
proved
highly
efficacious
both
impeding
primary/metastatic
eliciting
robust
tumor‐specific
response.
Collectively,
an
effective
delivery
synergized
therapy
pathway
activation‐mediated
immunotherapy
highlighted
here
provide
new
ideas
strategies
optimizing
combination
cancer
treatment.
Exploration,
Journal Year:
2024,
Volume and Issue:
4(6)
Published: March 22, 2024
Abstract
Metals
are
an
emerging
topic
in
cancer
immunotherapy
that
have
shown
great
potential
modulating
immunity
cycle
and
promoting
antitumor
by
activating
the
intrinsic
immunostimulatory
mechanisms
which
been
identified
recent
years.
The
main
challenge
of
metal‐assisted
lies
fact
free
metals
as
ion
forms
easily
cleared
during
circulation,
even
cause
systemic
metal
toxicity
due
to
off‐target
effects.
With
rapid
development
nanomedicine,
metal‐based
smart
nanosystems
(MSNs)
with
unique
controllable
structure
become
one
most
promising
delivery
carriers
solve
issue,
owing
their
various
endogenous/external
stimuli‐responsiveness
release
ions
for
metalloimmunotherapy.
In
this
review,
state‐of‐the‐art
research
progress
metal‐related
is
comprehensively
summarized.
First,
mainstream
MSNs‐assisted
will
be
delineated.
immunological
effects
certain
categorization
MSNs
different
characters
compositions
then
provided,
followed
representative
exemplar
applications
treatment,
synergistic
combination
immunotherapy.
Finally,
we
conclude
review
a
summary
remaining
challenges
associated
provide
authors'
perspective
on
further
advances.
Advanced Healthcare Materials,
Journal Year:
2023,
Volume and Issue:
12(19)
Published: March 11, 2023
Abstract
As
the
first
line
of
host
defense
against
pathogenic
infections,
innate
immunity
plays
a
key
role
in
antitumor
immunotherapy.
The
cyclic
GMP‐AMP
synthase
(cGAS)‐stimulator
interferon
genes
(STING)
(cGAS‐STING)
pathway
has
attracted
much
attention
because
secretion
various
proinflammatory
cytokines
and
chemokines.
Many
STING
agonists
have
been
identified
applied
into
preclinical
or
clinical
trials
for
cancer
However,
fast
excretion,
low
bioavailability,
nonspecificity,
adverse
effects
small
molecule
limit
their
therapeutic
efficacy
vivo
application.
Nanodelivery
systems
with
appropriate
size,
charge,
surface
modification
are
capable
addressing
these
dilemmas.
In
this
review,
mechanism
cGAS‐STING
is
discussed
agonists,
focusing
on
nanoparticle‐mediated
therapy
combined
cancers,
summarized.
Finally,
future
direction
challenges
nano‐STING
expounded,
emphasizing
pivotal
scientific
problems
technical
bottlenecks
hoping
to
provide
general
guidance
its
Journal of Inflammation Research,
Journal Year:
2023,
Volume and Issue:
Volume 16, P. 2089 - 2119
Published: May 1, 2023
Abstract:
Inflammatory
bowel
disease
(IBD),
including
Crohn's
(CD)
and
ulcerative
colitis
(UC),
is
a
group
of
chronic
inflammatory
diseases
the
gastrointestinal
tract.
Repeated
inflammation
can
lead
to
complications,
such
as
intestinal
fistula,
obstruction,
perforation,
bleeding.
Unfortunately,
achieving
durable
remission
mucosal
healing
(MH)
with
current
treatments
difficult.
Stem
cells
(SCs)
have
potential
modulate
immunity,
suppress
inflammation,
anti-apoptotic
pro-angiogenic
effects,
making
them
an
ideal
therapeutic
strategy
target
damage
in
IBD.
In
recent
years,
hematopoietic
stem
(HSCs)
adult
mesenchymal
(MSCs)
shown
efficacy
treating
addition,
numerous
clinical
trials
evaluated
efficiency
MSCs
disease.
This
review
summarizes
research
progress
on
safety
SC-based
therapy
for
IBD
both
preclinical
models
trials.
We
discuss
mechanisms
SC
therapy,
tissue
repair,
paracrine
promotion
angiogenesis,
immune
regulation,
anti-inflammatory
effects.
also
summarize
engineering
strategies
aimed
at
enhancing
immunosuppressive
regenerative
capabilities
SCs
diseases.
Additionally,
we
highlight
limitations
future
perspectives
SC-related
Graphic
Keywords:
cells,
stromal
HSCs,
immunosuppression,
disease,
colitis,
Biomaterials Research,
Journal Year:
2023,
Volume and Issue:
27(1)
Published: Feb. 9, 2023
The
activation
of
the
cyclic
guanosine
monophosphate-adenosine
monophosphate
synthase-stimulator
interferon
genes
(cGAS-STING)
signaling
pathway
has
attracted
great
attention
for
its
ability
to
up-regulate
innate
immune
response
and
thus
enhance
cancer
immunotherapy.
However,
many
STING
agonists
limit
further
advancement
immunotherapy
due
weak
tumor
responsiveness
or
low
efficiency.
responsive
effective
cGAS-STING
in
tumors
is
a
highly
challenging
process.
In
this
study,
manganese-based
nanoplatform
(MPCZ
NPs)
was
constructed
that
could
responsively
efficiently
generate
more
manganese
ions
(Mn2+)
reactive
oxygen
species
(ROS)
activate
pathway.
Briefly,
dioxide
(MnO2)
loaded
with
zinc
protoporphyrin
IX
(ZPP)
molecule
coated
by
polydopamine
(PDA)
embedded
NH4HCO3
obtain
MPCZ
NPs.
Additionally,
NPs
were
evaluated
vitro
vivo
their
antitumor
effects
methyl
thiazolyl
tetrazolium
(MTT)
assay
TUNEL
assays,
respectively.
system,
achieved
exogenous
(laser
irradiation)
endogenous
(high
levels
GSH)
stimulation,
which
triggered
collapse
degradation
PDA
MnO2.
Moreover,
release
Mn2+
augmented
enhanced
conversion
hydrogen
peroxide
(H2O2)
hydroxyl
radical
(·OH)
under
NIR
laser
irradiation.
Furthermore,
ZPP
elimination
GSH
inhibited
HO-1
activity
prevented
ROS
consumption,
This
adopted
open
source
reduce
expenditure
strategy
effectively
pathway,
providing
new
improving
